Pelvic Floor DisorderNCT06786091
Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment
A study testing Pelvic floor muscle training rehabilitation in people with Pelvic Floor Disorder and Female Pelvic Floor Dysfunction, run by St. Olavs Hospital at 2 sites in Norway.
Trial summary
Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system. Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Pelvic Floor Disorder, Female Pelvic Floor Dysfunction, Female Sexual Dysfunction
- What is being tested?
- Pelvic floor muscle training rehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 2 sitesNorway
- Study dates
- 4 Feb 2025to 1 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women diagnosed and treated for cervical cancer (surgery, radiation- or chemo therapy) within the last five years
- Cancer stadium I-III
- Adequate knowledge in Norwegian.
Who cannot join
- Previous pelvic radiation therapy or pelvic surgery.
Trial locations and contacts
2 sites in 1 country.
Norway2 sites
Østfold Hospital
Fredrikstad, Østfold fylke, 1714
St.Olavs University Hopsital
Trondheim, Trøndelag, 7030
About this study
Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system. Pelvic floor dysfunctions such as urinary- and anal incontinence, pelvic organ prolapse, vaginal stenosis as well as compromised sexual function and dyspareunia appear to be highly prevalent. The incidence of gynecological cancer in Norway was 1700 in 2020 and the survival rate in Norway is among the highest in the world. Most women with cervical cancers are treated with curative intension and life expectancy at 5 years after diagnosis is >80%.
A negative impact of pelvic floor disorders on psychosocial well-being and quality of life are seen in survivors of gynecological cancer, and in cancer survivors this is found to be directly linked with patients regaining continence. Pelvic floor muscle training has few or no side effects, and is acknowledged as first line treatment for all types of urinary incontinence in women. Even though less studied, there is evidence to support pelvic floor muscle training as a safe intervention to reduce symptoms of anal incontinence and improve sexual function. A recent comparative cross-sectional study found that survivors of gynecological cancer with dyspareunia had higher stiffness and lower flexibility, coordination and endurance of the pelvic floor muscles compared to women with a history of total hysterectomy but no pelvic pain. These findings suggest a possible role for pelvic floor muscle training in the prevention and treatment of pelvic floor disorders after gynecological cancer. However, the overall quality of evidence for strengthening the pelvic floor muscles to reduce symptoms of pelvic floor dysfunctions after treatment of gynecological cancer is low.
This study aims to assess the feasibility of a digital pelvic floor rehabilitation programme led by an experienced pelvic floor physiotherapist. Study subjects are women treated for cervical cancer within the past 5 years, and all included participants will receive the intervention due to the feasibility design. Participants will be assessed clinically at baseline and endpoint, partly to ensure proper pelvic floor muscle contraction. The digital intervention ensures residents in rural areas equal access to specialized pelvic floor rehabilitation.
Read the detailed description
Introduction:
The primary goal of cancer treatment is to cure the disease or considerably prolong life, and secondary to improve the patient's quality of life. However, more than 500 distinct kinds of late side effects have been associated with modern cancer therapy ranging from minor, asymptomatic changes to life-threatening injuries and death. Many cancer survivors do not regain their previous level of health and functioning. Thus, as life expectancy after cancer is increasing, more people are living with substantial and permanent bodily changes negatively affecting quality of life. Based on this, the Norwegian Women's Public Health Association (N.K.S.) has identified a knowledge gap in cancer treatment, with a main focus on prevention and treatment on late side-effects in "cancer affecting women" in the strategic research plan for 2018-2024.
Gynecological cancer includes cancer in the cervix, uterus, ovaries/fallopian tubes and vulva with an estimated global prevalence of 1.31 million new cases each year. Women diagnosed with uterine-, ovarian/fallopian tube and vulvar cancer are on average aged >60 years, while women diagnosed with cervical cancer are younger with a median age of 45 years. The incidence of gynecological cancer in Norway was 1700 in 2020b and the survival rate in Norway is among the highest in the world. Most women with cervical cancers are treated with curative intension and life expectancy at 5 years after diagnosis is >80%.
Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system. Pelvic floor dysfunctions such as urinary- and anal incontinence, pelvic organ prolapse, vaginal stenosis as well as compromised sexual function and dyspareunia appear to be highly prevalent. According to a recent systematic review including 31 studies of pelvic floor disorders in gynecological cancer survivors, prevalence of urinary incontinence was reported up to 76%, fecal incontinence up to 37% and dyspareunia up to 58%. However, study quality tended to be poor, and the need for more comparative data on pelvic floor disorders among gynecological cancer survivors and the general population is highlighted by several studies included in the review. A negative impact of pelvic floor disorders on psychosocial well-being and quality of life are seen in survivors of gynecological cancer, and in cancer survivors this is found to be directly linked with patients regaining continence.
Pelvic floor muscle training has few or no side effects, and is acknowledged as first line treatment for all types of urinary incontinence in women, and mild-moderate pelvic organ prolapse. Even though less studied, there is evidence to support pelvic floor muscle training as a safe intervention to reduce symptoms of anal incontinence and improve sexual function. The pelvic floor muscles is a three-layered muscle group covering the inside of the pelvis constituting the "floor" of the truncus. This muscle group encloses the urethra, vagina and rectum, and is involved in the continence mechanism, elimination, sexual arousal and support of the pelvic organs. There is evidence that structured pelvic floor muscle training increases muscle volume and stiffness, closes the levator hiatus and elevates the resting position of bladder and rectum.
Gynecologic cancer therapy often includes multiple treatment modalities, all which alone and in combination have the potential to affect the pelvic organs and the musculoskeletal system. Nonetheless, it is likely that pelvic floor disorders following cancer treatment are associated, at least in part, with a deterioration in pelvic floor muscle function. The functional properties of the pelvic floor muscles following treatment of gynecological cancer is poorly studied. One small study found that both passive and contractile properties of the pelvic floor muscles was altered in women with urinary incontinence following surgery and radiotherapy of stage I and II endometrial cancer compared to women with urinary incontinence after benign hysterectomy. A recent comparative cross-sectional study found that survivors of gynecological cancer with dyspareunia had higher stiffness and lower flexibility, coordination and endurance of the pelvic floor muscles compared to women with a history of total hysterectomy but no pelvic pain. These findings suggest a possible role for pelvic floor muscle training in the prevention and treatment of pelvic floor disorders after gynecological cancer.
Nevertheless, the overall quality of evidence for strengthening the pelvic floor muscles to reduce symptoms of pelvic floor dysfunctions after treatment of gynecological cancer is low. Some studies suggest a positive outcome of pelvic floor muscle training on symptoms of urinary incontinence, however these results lack statistical power and must be interpreted with caution. There is evidence to suggest that pelvic floor muscle training improves sexual function and dyspareunia, whereas there is scarce documentation of pelvic floor muscle training as treatment for anal incontinence following gynecological cancer. There is no clear evidence that regular vaginal dilatation reduces or prevent the risk of vaginal stenosis after pelvic radiotherapy. However, observational studies suggest a positive association with lower rates of self-reported stenosis, and recommending regular vaginal dilation after radiotherapy is established practice. Low compliance rates have been noted, and lack of sufficient information are the most commonly reported barrier, resulting in uncertainty about dilator use. Recently, Cyr et al. (2020) shoved good feasibility and acceptability of multimodal pelvic floor physical therapy, including pelvic floor muscle training and use of a dilator, for gynecological cancer survivors with dyspareunia. The intervention also led to significant improvements in pain, sexual function, pelvic floor dysfunction symptoms and quality of life.
Over the past decade there has been increasing research and clinical interest in the role of exercise as an adjunct therapy to improve symptom control and management following cancer diagnosis. More recently the research field has been extended beyond symptom control to also include evaluation of benefits for cancer-specific outcomes, cancer progression and metastasis. Overall, general exercise is recommended for cancer survivors and there is evidence that exercise may improve cancer-related health outcomes such as anxiety, symptoms of depression, body image/self-esteem, sleep disturbance, fatigue, physical functioning and health-related quality of life. Despite this, adherence to the recommended physical activity and exercise guidelines among cancer patients appears to be poor. A recent systematic scoping review found that cancer patients believed that physical activity and exercise was beneficial for their physical health and well-being. However, lack of support and treatment related side effects acted as barriers. Group exercising with other cancer patients who face similar challenges was a major facilitator among most participants. The authors calls for innovative healthcare products and technologies designed to help manage cancer related side effects and enhance compliance to physical activity and exercise guidelines.
The adverse effects from the pelvic region may have a slow trajectory of onset and are thus more prone to being overlooked by clinicians after the initial stages of treatment is over. Radical surgical interventions result in immediate symptoms with the potential for improvement with time, whereas radiation tends to elicit late effects that manifest over many months. As such, pelvic floor dysfunctions and sexual morbidity remains a neglected aspect of routine follow-up for cancer, and the user organization highlights the need for increased focus on sexual health in cancer rehabilitation. The topic is still a taboo inhibiting both patient and health care professionals, resulting in patients suffering with symptoms for a long time without seeking help. Community-based studies have shown that embarrassment, lack of knowledge about the causes, unfamiliarity with treatment options and the presence of concomitant symptoms are reasons for not seeking medical treatment. A qualitative study among gynecological cancer survivors found that most women reported their pelvic floor dysfunctions to be a direct consequence of the cancer treatment. Despite severe symptom burden and negative impact on quality of life, most women found their own ways of coping with these symptoms. Lack of knowledge about existing treatment options was the most frequently reported reason for not seeking help. In the same study, 11 out of 15 informants stated that post-treatment care should be improved with regards to information, prevention and management of pelvic floor disorder.
To summarize, surgery, radiotherapy and chemotherapy alone or in combination may induce detrimental long-term side-effects in survivors of gynecological cancer. In parallel, advances in cancer treatment improve survival rates and in combination with an increasingly older population, more women are living with adverse effects of cancer and cancer treatment. These developments have transformed the experience of cancer from a potentially life threatening illness, to the current interpretation of cancer as a long-term or chronic condition. Unfortunately, there is less focus on how to prevent late side-effects, and even less on how to treat them. This project aims to improve the knowledge base on prevention and treatment of late side-effects following gynecological cancer. More specific, the project objective are to assess:
Feasibility of a web-based education and exercise rehabilitation intervention to reduce late side-effects following treatment of cervical cancer.
Novelty and ambition:
The project is a response to research needs identified by the N.K.S. on "cancer affecting women" and "sexual and reproductive health". Further the project concurs with the N.K.S. research strategy 2018-2024 to reduce health discrepancies through equal access to healthcare. The project is according to Stiftelsen Dam's area of attention "patient and user centered research" aiming to promote health and quality of life and prevent known late effects in gynecological cancer survivors.
The novelty of this study is improving the knowledge of interventions preventing and reducing late side-effects of cervical cancer. The financial burden of late side-effects of cancer is large for patients as well as society. The financial burden may be further increased in the future with increasing direct costs related to medical care, and treatment for long-term side-effects, as well as indirect costs related to factors such as loss of productivity in combination with higher survival rates. Health literacy entails a person's knowledge, motivation and competences to access, understand, appraise and apply health information. During the life course, health literacy is vital and enables a person to evaluate and make informed decisions concerning health care, disease prevention and health promotion in order to maintain or improve quality of life. The Government's strategy (2020-2023)c aims to strengthen the active patient role with regards to health and treatment, and to facilitate services specifically tailored to the individual patient's needs. The use of new technology and health services that can be adapted to a greater extent in the patient's own home is highlighted.
The innovation potential in the present proposal is related to improved clinical pathways with increased focus on prevention and treatment of pelvic floor disorders. The intervention has a holistic approach with information and practical guidance empowering women to take on responsibility for their condition with appropriate clinical assessment, support and treatment. Exercise is a well-recognized and cost-effective intervention for musculoskeletal diseases in the general population, and results from this project will be the starting point of a full scale randomized controlled trial. Patient-centred care improves disease outcomes and quality of life and health literacy is mandatory for patients to make informed decisions and actions for themselves. A digitally supervised early education and rehabilitation intervention to prevent or reduce bothersome late side-effects following gynecological cancer will ensure patients equal access to specialized health care and rehabilitation regardless of where they live. Moreover, a digital intervention does not require physical attendance and is considered less burdensome as the patients do not need to travel and can follow the exercise group from their own homes. The intervention also facilitates contact with other survivors of gynecological cancer as the digital meetings opens 30 minutes prior to exercise to allow participants to chat with each other or ask questions to the physiotherapist. As the health care services are becoming more digitalized, the present proposal may also provide firsthand experience with digital exercise groups which may be useful to other clinical fields.
Research questions and hypotheses, theoretical approach and methodology:
The overall aim is to investigate the feasibility of an early digital education and exercise rehabilitation program.
Hypothesis:
A four month, twice weekly web-based education and exercise intervention is feasible and will result in a reduction in late symptoms of pelvic floor disorders and sexual dysfunction following treatment of cervical cancer.
Methodology:
The study design is an observational two-centre study. Participants and settings: Patients diagnosed with cervical cancer at St. Olavs Hospital, Trondheim University Hospital and Østfold Hospital Trust within the last five years are eligible for this study. We aim to include up to 40 women. Eligible women will be identified through outpatient cervical cancer control lists. We therefore apply exemption from the confidentiality principle. The unique eleven digit ID number will be used to invite eligible women through Eforsk. The inclusion criteria are women aged 18 years or over diagnosed and treated for cervical cancer (radical surgery or radiotherapy) within the last five years, cancer stadium I-III and adequate knowledge in Norwegian. Exclusion criteria are age >80 years, previous radiotherapy or pelvic surgery. Due to the design of a feasibility study, all included women will be offered the intervention. Study assessment visits: The clinical assessment visits are conducted with attendance at the outpatient clinic, Department of Physiotherapy. Baseline assessment will be done at study entry. Clinical assessment involves assessment of pelvic floor muscular strength and function. Strength and relaxation of the pelvic floor muscles are measured by a Camtech manometer. This involves the insertion of a small probe with a size smaller than a tampon into the vaginal opening. Further, strength and relaxation as well as muscular pain is assessed by internal palpation of the pelvic floor muscles in the vaginal opening. Some of the patients at St.Olavs hospital will be assessed by transperineal ultra sound imaging, involving an ultra sound probe at the perineum. The patients are reassessed after the 16-week intervention period. If the patient needs further individualized follow-up, contact will be established with a local primary health care physiotherapist. If relevant, patients will be referred to a gynecologist or sexual counselling.
Intervention:
The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation (pelvic floor muscle training and use of dilator) is supported with written information. The exercise program (aerobic and strength training, including pelvic floor muscle training) is provided with supervised digital group exercise sessions twice weekly and a home exercise program once weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage. The supervised digital exercise sessions are provided via www.join.nhn.no (Norsk Helsenett), and all sessions will open 30 minutes prior to exercise to allow for informal talk among participants and response to questions related to their treatment or training from the physiotherapist. Women will be offered individual video consultations for motivational talk in addition to the group sessions. Adherence to the exercise program is strongly emphasized and will be recorded in the patients' personal training diaries. Attendance in the digital group exercise will be registered by physiotherapists leading the group. Women not attending the group exercise sessions without prior notice will be contacted by telephone.
Outcome measures:
The primary outcome measures are to assess the willingness of participants to be included, their adherence and compliance to the intervention and response to the symptom questionnaires.
Secondary outcome measures are symptoms and severity of pelvic floor disorders, sexual function, lymphedema, quality of life and level of physical activity. Urinary incontinence are assessed using the International Consultation on Incontinence Questionnaire-UI Short Form (ICIQ-UI SF), an outcome measure developed to assess prevalence, severity, impact on quality of life and type of leakage. The short form has demonstrated satisfactory validity, reliability and sensitivity. Severity of anal incontinence symptoms is assessed with the widely used St.Marks incontinence score. The St. Marks score assesses frequency of stool and gas leakage, impact on daily life, urgency, pad use and use of constipating medication. Sexual dysfunction is assessed using the Amsterdam hyperactive pelvic floor scale (AHPFS) , the Female Sexual Distress Scale- revised (FSDS-R) and the Female Sexual Function Index. Quality of life is measured with The European Organization for Research and Treatment of Cancer Quality of Life core questionnaire (EORTC QLQ-C30) and QLQ-CX24. EORTC QLQ-C30 is a disease-specific instrument that is the instrument of choice in cancer trials in Europe. The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and QOL scale. QLQ-CX24 is a cervical cancer-specific quality of life questionnaire module to be used in conjunction with QLQ-C30. Patient's impression of change is assessed by the Patient Global Impression of Change (PGIC). Secondary lymphedema will be assessed by the gynecologic cancer lymphedema questionnaire (GCLQ). Data regarding cancer diagnosis, treatment and potential medical events during the follow-up period will be collected from the patient medical records. Additionally, re-admission to hospital, ICD-10 diagnostic codes and in-hospital time will be recorded from the hospital records up to 12 months after completion of the chosen cancer treatment. In addition to the disease specific questionnaires, relevant baseline characteristics such as age, parity, type of delivery, menopause and vaginal supportive care, social status, education, frequency of physical activity, exercise activity and pelvic floor muscle training are collected on an digital questionnaire (eFORSK, https://www.klinforsk.no/info/Informasjon). Possible adverse events are recorded according to the CONSORT guidelines.
Statistics:
Statistical analysis include descriptive statistics, parametric tests for normal distributed data and non-parametric tests for skewed data
Sample size:
A power calculation is usually not advised when conduction a feasibility study, however, the sample size should be adequate to estimate critical parameters such as recruitment rate. Thus, it is suggested that recruiting 40 women may be sufficient.
User participation:
User involvement is ensured by including two members from patient interest organizations (Kreftforeningen and Gynkreftforeningen). The users are both survivors of gynecological cancer and trained in user involvement in research. So far, they have been consulted and provided valuable input on design of the intervention and follow-up. Further, they will be involved in the development and adaptation of the communication materials, and selection of questionnaires. The users are named as co-applicant for the funding and their time and travel expenses related to the project will be reimbursed. The phd-student will be the key person within the research team for users to contact. Further, N.K.S. research consultant Ida Heiaas and the N.K.S. "Womens health centre group" has contributed to the development of the study protocol.
- Conditions
- Pelvic Floor Disorder, Female Pelvic Floor Dysfunction, Female Sexual Dysfunction, Female Urinary Incontinence, Fecal Incontinence, Secondary Lymphedema
- Being tested
- Pelvic floor muscle training rehabilitation
- Keywords
- feasibility studies, cervical cancer, pelvic floor muscle training, quality of life, pelvic floor morphology, pelvic floor muscle strength
- Medical subject headings
- Pelvic Floor Disorders, Fecal Incontinence, Pelvic Pain, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pelvic floor muscle training rehabilitationOther
The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation is supported with written information. The exercise program is provided with supervised digital group exercise sessions twice weekly and a home exercise program 4-5 weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage i.e. 3 sets of 10-12 repetitions, 5-7 times per week.
| Study group | Role | What they receive |
|---|---|---|
| Digital pelvic floor exercise group | Experimental | Not described Receives: Other: Pelvic floor muscle training rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility - participants willingness to be included
Participants willingness to be included (measured by inclusion rate i.e. how many are included out of the total number asked)
Measured: The time frame is pre-defined as one year recruitment period
Adherence - participants adherence to the intervention
Participants adherence to the intervention, measured by how many group exercises they part-take in out of the total number of 32 group exercises
Measured: From enrollment until the end of the treatment at 16 weeks
Compliance to home exercises
Participants compliance to the intervention. Participants are encouraged to do home exercises 3 times weekly (equals 48 exercise sessions over the intervention period). This is measured through reports in their training diary.
Measured: From enrollment until the end of the treatment at 16 weeks
Participants impression of change
Participants impression of change following the intervention, measured by the Patient Global Impression of Change. Scale from 1-7, higher score indicating better outcome.
Measured: From enrollment until the end of the treatment at 16 weeks
Secondary outcomes (17)
Symptoms of urinary incontinence
Measured by the International Consultation on Incontinence Questionnaire-UI Short Form, ICIQ-UI SF. Scale from 0-21, higher scores indicating worse outcomes.
Measured: From enrollment until the end of the treatment at 16 weeks
Symptoms and severity of anal incontinence
Measured by the St.Marks incontinence score. Scale from 0-24, higher scores indicating better worse outcomes.
Measured: From enrollment until the end of the treatment at 16 weeks
Symptoms of bowel dysfunction
Measured with the Low Anterior Resection Syndrome Score - LARS Score. Scale from 0-42, higher scores indicating worse outcome.
Measured: From enrollment until the end of the treatment at 16 weeks
Symptoms of sexual dysfunction
Measured by the Female Sexual Function Index. Scale ranging from 2-36, higher scores indicating better outcomes.
Measured: From enrollment until the end of the treatment at 16 weeks
Pelvic pain symptoms
Pelvic pain symptoms, possibly due to an abnormally high-toned pelvic floor muscle measured by the 16-item Amsterdam Complex Pelvic Pain Symptom Scale (ACPPS-16). Scores range from 16-80, higher scores indicating worse outcomes.
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Symptoms of sexual distress
Measured with the FSDS-R Female sexual distress scale - revised. Scores range from 0-42, higher scores indicate greater sexual distress (worse outcome).
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Quality of life questionnaire (EORTC QLQ-C30)
Measured with The European Organization for Research and Treatment of Cancer Quality of Life core questionnaire (EORTC QLQ-C30) ,higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
Measured: From enrollment until the end of the treatment at 16 weeks
Quality of life QLQ-CX24
Measured with The European Organization for Research and Treatment of Cancer Quality of Life core questionnaire QLQ-CX24.higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
Measured: From enrollment until the end of the treatment at 16 weeks
Symptoms of secondary lower limb lymphedema
Measured with the Gynecologic Cancer Lymphedema Questionnaire (GCLQ). Scores range from 0 to 20, higher scores indicating worse outcome.
Measured: From enrollment until the end of the treatment at 16 weeks
Pelvic floor muscle strength (digital palpation)
Measured with the Oxford scale, scores ranging from 0-5, higher scores indicating higher level of muscle strength.
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pelvic floor muscle strength (pressure manometer)
Pelvic floor muscle strength measured on a pressure manometer, higher pressure indicating higher strength level (the Camtech Manometer).
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pelvic floor muscle resting tone
Measured with a pressure manometer (the Camtech Manometer). Lower sores associated with lower resting tone, higher scores indicating higher muscle resting tone.
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pain sensitization of the vestibulum
Measured by the Q tip test, measured at a dichotomous level; presence of pain: yes/no
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pelvic floor muscle morphology
Expressed at the change in the levator hiatal area (4D ultrasound) and distance between the symphysis and the puborectal muscle (2D ultrasound). Transperineal ultrasound imaging is planned for some of the included patients as part of the feasibility design.
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Physical activity (frequency)
How often are you physically active? (By physically active we mean for instance walking, cross country skiing, cycling, swimming, running, or doing sports/exercise). Categorical (1) never, 2) less than once per week, 3) once per week, 4) 2-3 times per week, 5) every day)
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Physical activity (intensity)
If you do physical activity once per week or more; how hard do you exercise? Categorical; 1) Easy, without sweating or shortness of breath, 2) So hard that I sweat and get out of breath, 3) So hard that I go all out.
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Physical activity (how long)
How long are you physically active each time? Categorical; 1) Less than 15 minutes, 2) 15-29 minutes, 3) 30-60 minutes, 4) More than 60 minutes.
Measured: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2025
- Study start4 Feb 2025
- Primary completion10 Feb 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (58)Papers the sponsor has linked to this study.
- Other trials for Pelvic Floor DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- St. Olavs Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Sykehuset Ostfold
- Responsible party
- Sponsor
- Investigators
- Signe Nilssen Stafne, Study chair, St. Olavs Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06786091
- Sponsor's protocol ID
- 234097
- Other IDs
- 2023/FO426546
- Status last verified
- Aug 2026
- First submitted
- 3 Jan 2025
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012 May;255(5):922-8. doi: 10.1097/SLA.0b013e31824f1c21.
PubMed 22504191Deutekom M, Dobben AC, Dijkgraaf MG, Terra MP, Stoker J, Bossuyt PM. Costs of outpatients with fecal incontinence. Scand J Gastroenterol. 2005 May;40(5):552-8. doi: 10.1080/00365520510012172.
PubMed 16036507Xu X, Menees SB, Zochowski MK, Fenner DE. Economic cost of fecal incontinence. Dis Colon Rectum. 2012 May;55(5):586-98. doi: 10.1097/DCR.0b013e31823dfd6d.
PubMed 22513438Bjerre Trent P, Falk RS, Staff AC, Jorde D, Eriksson AG. Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire. Int J Gynecol Cancer. 2023 Feb 6;33(2):231-235. doi: 10.1136/ijgc-2022-003979.
PubMed 36600491Eidenberger M. Patient-Reported Outcome Measures With Secondary Lower Limb Lymphedemas: A Systematic Review. J Adv Pract Oncol. 2021 Mar;12(2):174-187. doi: 10.6004/jadpro.2021.12.2.5. Epub 2021 Mar 1.
PubMed 34109049Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163-70. doi: 10.1179/jmt.2009.17.3.163.
PubMed 20046623Abrams D, Davidson M, Harrick J, Harcourt P, Zylinski M, Clancy J. Monitoring the change: current trends in outcome measure usage in physiotherapy. Man Ther. 2006 Feb;11(1):46-53. doi: 10.1016/j.math.2005.02.003.
PubMed 15886046Perrot S, Lanteri-Minet M. Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice. Eur J Pain. 2019 Jul;23(6):1117-1128. doi: 10.1002/ejp.1378. Epub 2019 Mar 18.
PubMed 30793414Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015 Sep 14;1(1):e000146. doi: 10.1136/rmdopen-2015-000146. eCollection 2015.
PubMed 26535150Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33. doi: 10.1016/s0959-8049(01)00448-8.
PubMed 11858978Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
PubMed 8433390Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597.
PubMed 10782451DeRogatis L, Pyke R, McCormack J, Hunter A, Harding G. Does the Female Sexual Distress Scale-Revised cover the feelings of women with HSDD? J Sex Med. 2011 Oct;8(10):2810-5. doi: 10.1111/j.1743-6109.2011.02385.x. Epub 2011 Jul 19.
PubMed 21771282Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008 Feb;5(2):357-64. doi: 10.1111/j.1743-6109.2007.00672.x. Epub 2007 Nov 27.
PubMed 18042215Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002 Jul-Sep;28(4):317-30. doi: 10.1080/00926230290001448.
PubMed 12082670
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment
- ClinicalTrials.gov ID
- NCT06786091
- Acronym / sponsor ID
- 234097
- Conditions
- Pelvic Floor Disorder, Female Pelvic Floor Dysfunction, Female Sexual Dysfunction, Female Urinary Incontinence, Fecal Incontinence, Secondary Lymphedema
- Keywords
- feasibility studies, cervical cancer, pelvic floor muscle training, quality of life, pelvic floor morphology, pelvic floor muscle strength
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- St. Olavs HospitalUniversity, hospital or other
- Collaborators
- Sykehuset Ostfold
- Study start
- 4 Feb 2025 (actual)
- Primary completion
- 10 Feb 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 22 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system. Pelvic floor dysfunctions such as urinary- and anal incontinence, pelvic organ prolapse, vaginal stenosis as well as compromised sexual function and dyspareunia appear to be highly prevalent. The incidence of gynecological cancer in Norway was 1700 in 2020 and the survival rate in Norway is among the highest in the world. Most women with cervical cancers are treated with curative intension and life expectancy at 5 years after diagnosis is >80%.
A negative impact of pelvic floor disorders on psychosocial well-being and quality of life are seen in survivors of gynecological cancer, and in cancer survivors this is found to be directly linked with patients regaining continence. Pelvic floor muscle training has few or no side effects, and is acknowledged as first line treatment for all types of urinary incontinence in women. Even though less studied, there is evidence to support pelvic floor muscle training as a safe intervention to reduce symptoms of anal incontinence and improve sexual function. A recent comparative cross-sectional study found that survivors of gynecological cancer with dyspareunia had higher stiffness and lower flexibility, coordination and endurance of the pelvic floor muscles compared to women with a history of total hysterectomy but no pelvic pain. These findings suggest a possible role for pelvic floor muscle training in the prevention and treatment of pelvic floor disorders after gynecological cancer. However, the overall quality of evidence for strengthening the pelvic floor muscles to reduce symptoms of pelvic floor dysfunctions after treatment of gynecological cancer is low.
This study aims to assess the feasibility of a digital pelvic floor rehabilitation programme led by an experienced pelvic floor physiotherapist. Study subjects are women treated for cervical cancer within the past 5 years, and all included participants will receive the intervention due to the feasibility design. Participants will be assessed clinically at baseline and endpoint, partly to ensure proper pelvic floor muscle contraction. The digital intervention ensures residents in rural areas equal access to specialized pelvic floor rehabilitation.
Detailed description
Introduction:
The primary goal of cancer treatment is to cure the disease or considerably prolong life, and secondary to improve the patient's quality of life. However, more than 500 distinct kinds of late side effects have been associated with modern cancer therapy ranging from minor, asymptomatic changes to life-threatening injuries and death. Many cancer survivors do not regain their previous level of health and functioning. Thus, as life expectancy after cancer is increasing, more people are living with substantial and permanent bodily changes negatively affecting quality of life. Based on this, the Norwegian Women's Public Health Association (N.K.S.) has identified a knowledge gap in cancer treatment, with a main focus on prevention and treatment on late side-effects in "cancer affecting women" in the strategic research plan for 2018-2024.
Gynecological cancer includes cancer in the cervix, uterus, ovaries/fallopian tubes and vulva with an estimated global prevalence of 1.31 million new cases each year. Women diagnosed with uterine-, ovarian/fallopian tube and vulvar cancer are on average aged >60 years, while women diagnosed with cervical cancer are younger with a median age of 45 years. The incidence of gynecological cancer in Norway was 1700 in 2020b and the survival rate in Norway is among the highest in the world. Most women with cervical cancers are treated with curative intension and life expectancy at 5 years after diagnosis is >80%.
Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system. Pelvic floor dysfunctions such as urinary- and anal incontinence, pelvic organ prolapse, vaginal stenosis as well as compromised sexual function and dyspareunia appear to be highly prevalent. According to a recent systematic review including 31 studies of pelvic floor disorders in gynecological cancer survivors, prevalence of urinary incontinence was reported up to 76%, fecal incontinence up to 37% and dyspareunia up to 58%. However, study quality tended to be poor, and the need for more comparative data on pelvic floor disorders among gynecological cancer survivors and the general population is highlighted by several studies included in the review. A negative impact of pelvic floor disorders on psychosocial well-being and quality of life are seen in survivors of gynecological cancer, and in cancer survivors this is found to be directly linked with patients regaining continence.
Pelvic floor muscle training has few or no side effects, and is acknowledged as first line treatment for all types of urinary incontinence in women, and mild-moderate pelvic organ prolapse. Even though less studied, there is evidence to support pelvic floor muscle training as a safe intervention to reduce symptoms of anal incontinence and improve sexual function. The pelvic floor muscles is a three-layered muscle group covering the inside of the pelvis constituting the "floor" of the truncus. This muscle group encloses the urethra, vagina and rectum, and is involved in the continence mechanism, elimination, sexual arousal and support of the pelvic organs. There is evidence that structured pelvic floor muscle training increases muscle volume and stiffness, closes the levator hiatus and elevates the resting position of bladder and rectum.
Gynecologic cancer therapy often includes multiple treatment modalities, all which alone and in combination have the potential to affect the pelvic organs and the musculoskeletal system. Nonetheless, it is likely that pelvic floor disorders following cancer treatment are associated, at least in part, with a deterioration in pelvic floor muscle function. The functional properties of the pelvic floor muscles following treatment of gynecological cancer is poorly studied. One small study found that both passive and contractile properties of the pelvic floor muscles was altered in women with urinary incontinence following surgery and radiotherapy of stage I and II endometrial cancer compared to women with urinary incontinence after benign hysterectomy. A recent comparative cross-sectional study found that survivors of gynecological cancer with dyspareunia had higher stiffness and lower flexibility, coordination and endurance of the pelvic floor muscles compared to women with a history of total hysterectomy but no pelvic pain. These findings suggest a possible role for pelvic floor muscle training in the prevention and treatment of pelvic floor disorders after gynecological cancer.
Nevertheless, the overall quality of evidence for strengthening the pelvic floor muscles to reduce symptoms of pelvic floor dysfunctions after treatment of gynecological cancer is low. Some studies suggest a positive outcome of pelvic floor muscle training on symptoms of urinary incontinence, however these results lack statistical power and must be interpreted with caution. There is evidence to suggest that pelvic floor muscle training improves sexual function and dyspareunia, whereas there is scarce documentation of pelvic floor muscle training as treatment for anal incontinence following gynecological cancer. There is no clear evidence that regular vaginal dilatation reduces or prevent the risk of vaginal stenosis after pelvic radiotherapy. However, observational studies suggest a positive association with lower rates of self-reported stenosis, and recommending regular vaginal dilation after radiotherapy is established practice. Low compliance rates have been noted, and lack of sufficient information are the most commonly reported barrier, resulting in uncertainty about dilator use. Recently, Cyr et al. (2020) shoved good feasibility and acceptability of multimodal pelvic floor physical therapy, including pelvic floor muscle training and use of a dilator, for gynecological cancer survivors with dyspareunia. The intervention also led to significant improvements in pain, sexual function, pelvic floor dysfunction symptoms and quality of life.
Over the past decade there has been increasing research and clinical interest in the role of exercise as an adjunct therapy to improve symptom control and management following cancer diagnosis. More recently the research field has been extended beyond symptom control to also include evaluation of benefits for cancer-specific outcomes, cancer progression and metastasis. Overall, general exercise is recommended for cancer survivors and there is evidence that exercise may improve cancer-related health outcomes such as anxiety, symptoms of depression, body image/self-esteem, sleep disturbance, fatigue, physical functioning and health-related quality of life. Despite this, adherence to the recommended physical activity and exercise guidelines among cancer patients appears to be poor. A recent systematic scoping review found that cancer patients believed that physical activity and exercise was beneficial for their physical health and well-being. However, lack of support and treatment related side effects acted as barriers. Group exercising with other cancer patients who face similar challenges was a major facilitator among most participants. The authors calls for innovative healthcare products and technologies designed to help manage cancer related side effects and enhance compliance to physical activity and exercise guidelines.
The adverse effects from the pelvic region may have a slow trajectory of onset and are thus more prone to being overlooked by clinicians after the initial stages of treatment is over. Radical surgical interventions result in immediate symptoms with the potential for improvement with time, whereas radiation tends to elicit late effects that manifest over many months. As such, pelvic floor dysfunctions and sexual morbidity remains a neglected aspect of routine follow-up for cancer, and the user organization highlights the need for increased focus on sexual health in cancer rehabilitation. The topic is still a taboo inhibiting both patient and health care professionals, resulting in patients suffering with symptoms for a long time without seeking help. Community-based studies have shown that embarrassment, lack of knowledge about the causes, unfamiliarity with treatment options and the presence of concomitant symptoms are reasons for not seeking medical treatment. A qualitative study among gynecological cancer survivors found that most women reported their pelvic floor dysfunctions to be a direct consequence of the cancer treatment. Despite severe symptom burden and negative impact on quality of life, most women found their own ways of coping with these symptoms. Lack of knowledge about existing treatment options was the most frequently reported reason for not seeking help. In the same study, 11 out of 15 informants stated that post-treatment care should be improved with regards to information, prevention and management of pelvic floor disorder.
To summarize, surgery, radiotherapy and chemotherapy alone or in combination may induce detrimental long-term side-effects in survivors of gynecological cancer. In parallel, advances in cancer treatment improve survival rates and in combination with an increasingly older population, more women are living with adverse effects of cancer and cancer treatment. These developments have transformed the experience of cancer from a potentially life threatening illness, to the current interpretation of cancer as a long-term or chronic condition. Unfortunately, there is less focus on how to prevent late side-effects, and even less on how to treat them. This project aims to improve the knowledge base on prevention and treatment of late side-effects following gynecological cancer. More specific, the project objective are to assess:
Feasibility of a web-based education and exercise rehabilitation intervention to reduce late side-effects following treatment of cervical cancer.
Novelty and ambition:
The project is a response to research needs identified by the N.K.S. on "cancer affecting women" and "sexual and reproductive health". Further the project concurs with the N.K.S. research strategy 2018-2024 to reduce health discrepancies through equal access to healthcare. The project is according to Stiftelsen Dam's area of attention "patient and user centered research" aiming to promote health and quality of life and prevent known late effects in gynecological cancer survivors.
The novelty of this study is improving the knowledge of interventions preventing and reducing late side-effects of cervical cancer. The financial burden of late side-effects of cancer is large for patients as well as society. The financial burden may be further increased in the future with increasing direct costs related to medical care, and treatment for long-term side-effects, as well as indirect costs related to factors such as loss of productivity in combination with higher survival rates. Health literacy entails a person's knowledge, motivation and competences to access, understand, appraise and apply health information. During the life course, health literacy is vital and enables a person to evaluate and make informed decisions concerning health care, disease prevention and health promotion in order to maintain or improve quality of life. The Government's strategy (2020-2023)c aims to strengthen the active patient role with regards to health and treatment, and to facilitate services specifically tailored to the individual patient's needs. The use of new technology and health services that can be adapted to a greater extent in the patient's own home is highlighted.
The innovation potential in the present proposal is related to improved clinical pathways with increased focus on prevention and treatment of pelvic floor disorders. The intervention has a holistic approach with information and practical guidance empowering women to take on responsibility for their condition with appropriate clinical assessment, support and treatment. Exercise is a well-recognized and cost-effective intervention for musculoskeletal diseases in the general population, and results from this project will be the starting point of a full scale randomized controlled trial. Patient-centred care improves disease outcomes and quality of life and health literacy is mandatory for patients to make informed decisions and actions for themselves. A digitally supervised early education and rehabilitation intervention to prevent or reduce bothersome late side-effects following gynecological cancer will ensure patients equal access to specialized health care and rehabilitation regardless of where they live. Moreover, a digital intervention does not require physical attendance and is considered less burdensome as the patients do not need to travel and can follow the exercise group from their own homes. The intervention also facilitates contact with other survivors of gynecological cancer as the digital meetings opens 30 minutes prior to exercise to allow participants to chat with each other or ask questions to the physiotherapist. As the health care services are becoming more digitalized, the present proposal may also provide firsthand experience with digital exercise groups which may be useful to other clinical fields.
Research questions and hypotheses, theoretical approach and methodology:
The overall aim is to investigate the feasibility of an early digital education and exercise rehabilitation program.
Hypothesis:
A four month, twice weekly web-based education and exercise intervention is feasible and will result in a reduction in late symptoms of pelvic floor disorders and sexual dysfunction following treatment of cervical cancer.
Methodology:
The study design is an observational two-centre study. Participants and settings: Patients diagnosed with cervical cancer at St. Olavs Hospital, Trondheim University Hospital and Østfold Hospital Trust within the last five years are eligible for this study. We aim to include up to 40 women. Eligible women will be identified through outpatient cervical cancer control lists. We therefore apply exemption from the confidentiality principle. The unique eleven digit ID number will be used to invite eligible women through Eforsk. The inclusion criteria are women aged 18 years or over diagnosed and treated for cervical cancer (radical surgery or radiotherapy) within the last five years, cancer stadium I-III and adequate knowledge in Norwegian. Exclusion criteria are age >80 years, previous radiotherapy or pelvic surgery. Due to the design of a feasibility study, all included women will be offered the intervention. Study assessment visits: The clinical assessment visits are conducted with attendance at the outpatient clinic, Department of Physiotherapy. Baseline assessment will be done at study entry. Clinical assessment involves assessment of pelvic floor muscular strength and function. Strength and relaxation of the pelvic floor muscles are measured by a Camtech manometer. This involves the insertion of a small probe with a size smaller than a tampon into the vaginal opening. Further, strength and relaxation as well as muscular pain is assessed by internal palpation of the pelvic floor muscles in the vaginal opening. Some of the patients at St.Olavs hospital will be assessed by transperineal ultra sound imaging, involving an ultra sound probe at the perineum. The patients are reassessed after the 16-week intervention period. If the patient needs further individualized follow-up, contact will be established with a local primary health care physiotherapist. If relevant, patients will be referred to a gynecologist or sexual counselling.
Intervention:
The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation (pelvic floor muscle training and use of dilator) is supported with written information. The exercise program (aerobic and strength training, including pelvic floor muscle training) is provided with supervised digital group exercise sessions twice weekly and a home exercise program once weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage. The supervised digital exercise sessions are provided via www.join.nhn.no (Norsk Helsenett), and all sessions will open 30 minutes prior to exercise to allow for informal talk among participants and response to questions related to their treatment or training from the physiotherapist. Women will be offered individual video consultations for motivational talk in addition to the group sessions. Adherence to the exercise program is strongly emphasized and will be recorded in the patients' personal training diaries. Attendance in the digital group exercise will be registered by physiotherapists leading the group. Women not attending the group exercise sessions without prior notice will be contacted by telephone.
Outcome measures:
The primary outcome measures are to assess the willingness of participants to be included, their adherence and compliance to the intervention and response to the symptom questionnaires.
Secondary outcome measures are symptoms and severity of pelvic floor disorders, sexual function, lymphedema, quality of life and level of physical activity. Urinary incontinence are assessed using the International Consultation on Incontinence Questionnaire-UI Short Form (ICIQ-UI SF), an outcome measure developed to assess prevalence, severity, impact on quality of life and type of leakage. The short form has demonstrated satisfactory validity, reliability and sensitivity. Severity of anal incontinence symptoms is assessed with the widely used St.Marks incontinence score. The St. Marks score assesses frequency of stool and gas leakage, impact on daily life, urgency, pad use and use of constipating medication. Sexual dysfunction is assessed using the Amsterdam hyperactive pelvic floor scale (AHPFS) , the Female Sexual Distress Scale- revised (FSDS-R) and the Female Sexual Function Index. Quality of life is measured with The European Organization for Research and Treatment of Cancer Quality of Life core questionnaire (EORTC QLQ-C30) and QLQ-CX24. EORTC QLQ-C30 is a disease-specific instrument that is the instrument of choice in cancer trials in Europe. The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and QOL scale. QLQ-CX24 is a cervical cancer-specific quality of life questionnaire module to be used in conjunction with QLQ-C30. Patient's impression of change is assessed by the Patient Global Impression of Change (PGIC). Secondary lymphedema will be assessed by the gynecologic cancer lymphedema questionnaire (GCLQ). Data regarding cancer diagnosis, treatment and potential medical events during the follow-up period will be collected from the patient medical records. Additionally, re-admission to hospital, ICD-10 diagnostic codes and in-hospital time will be recorded from the hospital records up to 12 months after completion of the chosen cancer treatment. In addition to the disease specific questionnaires, relevant baseline characteristics such as age, parity, type of delivery, menopause and vaginal supportive care, social status, education, frequency of physical activity, exercise activity and pelvic floor muscle training are collected on an digital questionnaire (eFORSK, https://www.klinforsk.no/info/Informasjon). Possible adverse events are recorded according to the CONSORT guidelines.
Statistics:
Statistical analysis include descriptive statistics, parametric tests for normal distributed data and non-parametric tests for skewed data
Sample size:
A power calculation is usually not advised when conduction a feasibility study, however, the sample size should be adequate to estimate critical parameters such as recruitment rate. Thus, it is suggested that recruiting 40 women may be sufficient.
User participation:
User involvement is ensured by including two members from patient interest organizations (Kreftforeningen and Gynkreftforeningen). The users are both survivors of gynecological cancer and trained in user involvement in research. So far, they have been consulted and provided valuable input on design of the intervention and follow-up. Further, they will be involved in the development and adaptation of the communication materials, and selection of questionnaires. The users are named as co-applicant for the funding and their time and travel expenses related to the project will be reimbursed. The phd-student will be the key person within the research team for users to contact. Further, N.K.S. research consultant Ida Heiaas and the N.K.S. "Womens health centre group" has contributed to the development of the study protocol.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Digital pelvic floor exercise group | Experimental | Other: Pelvic floor muscle training rehabilitation |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Women diagnosed and treated for cervical cancer (surgery, radiation- or chemo therapy) within the last five years
- Cancer stadium I-III
- Adequate knowledge in Norwegian.
Key exclusion criteria (1 listed)
- Previous pelvic radiation therapy or pelvic surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pelvic floor muscle training rehabilitationThe intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation is supported with written information. The exercise program is provided with supervised digital group exercise sessions twice weekly and a home exercise program 4-5 weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage i.e. 3 sets of 10-12 repetitions, 5-7 times per week. | Other | Digital pelvic floor exercise group |
Primary outcome
Feasibility - participants willingness to be included
Time frame: The time frame is pre-defined as one year recruitment period
Participants willingness to be included (measured by inclusion rate i.e. how many are included out of the total number asked)
Adherence - participants adherence to the intervention
Time frame: From enrollment until the end of the treatment at 16 weeks
Participants adherence to the intervention, measured by how many group exercises they part-take in out of the total number of 32 group exercises
Compliance to home exercises
Time frame: From enrollment until the end of the treatment at 16 weeks
Participants compliance to the intervention. Participants are encouraged to do home exercises 3 times weekly (equals 48 exercise sessions over the intervention period). This is measured through reports in their training diary.
Participants impression of change
Time frame: From enrollment until the end of the treatment at 16 weeks
Participants impression of change following the intervention, measured by the Patient Global Impression of Change. Scale from 1-7, higher score indicating better outcome.
17 secondary outcomes
Symptoms of urinary incontinence
Time frame: From enrollment until the end of the treatment at 16 weeks
Symptoms and severity of anal incontinence
Time frame: From enrollment until the end of the treatment at 16 weeks
Symptoms of bowel dysfunction
Time frame: From enrollment until the end of the treatment at 16 weeks
Symptoms of sexual dysfunction
Time frame: From enrollment until the end of the treatment at 16 weeks
Pelvic pain symptoms
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Symptoms of sexual distress
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Quality of life questionnaire (EORTC QLQ-C30)
Time frame: From enrollment until the end of the treatment at 16 weeks
Quality of life QLQ-CX24
Time frame: From enrollment until the end of the treatment at 16 weeks
Symptoms of secondary lower limb lymphedema
Time frame: From enrollment until the end of the treatment at 16 weeks
Pelvic floor muscle strength (digital palpation)
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pelvic floor muscle strength (pressure manometer)
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pelvic floor muscle resting tone
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pain sensitization of the vestibulum
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Pelvic floor muscle morphology
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Physical activity (frequency)
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Physical activity (intensity)
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Physical activity (how long)
Time frame: From baseline clinical examination until endpoint clinical examination (after 16 weeks intervention)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Background: PubMed 22504191Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012 May;255(5):922-8. doi: 10.1097/SLA.0b013e31824f1c21.
- Background: PubMed 16036507Deutekom M, Dobben AC, Dijkgraaf MG, Terra MP, Stoker J, Bossuyt PM. Costs of outpatients with fecal incontinence. Scand J Gastroenterol. 2005 May;40(5):552-8. doi: 10.1080/00365520510012172.
- Background: PubMed 22513438Xu X, Menees SB, Zochowski MK, Fenner DE. Economic cost of fecal incontinence. Dis Colon Rectum. 2012 May;55(5):586-98. doi: 10.1097/DCR.0b013e31823dfd6d.
- Background: PubMed 36600491Bjerre Trent P, Falk RS, Staff AC, Jorde D, Eriksson AG. Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire. Int J Gynecol Cancer. 2023 Feb 6;33(2):231-235. doi: 10.1136/ijgc-2022-003979.
- Background: PubMed 34109049Eidenberger M. Patient-Reported Outcome Measures With Secondary Lower Limb Lymphedemas: A Systematic Review. J Adv Pract Oncol. 2021 Mar;12(2):174-187. doi: 10.6004/jadpro.2021.12.2.5. Epub 2021 Mar 1.
- Background: PubMed 20046623Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163-70. doi: 10.1179/jmt.2009.17.3.163.
- Background: PubMed 15886046Abrams D, Davidson M, Harrick J, Harcourt P, Zylinski M, Clancy J. Monitoring the change: current trends in outcome measure usage in physiotherapy. Man Ther. 2006 Feb;11(1):46-53. doi: 10.1016/j.math.2005.02.003.
- Background: PubMed 30793414Perrot S, Lanteri-Minet M. Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice. Eur J Pain. 2019 Jul;23(6):1117-1128. doi: 10.1002/ejp.1378. Epub 2019 Mar 18.
- Background: PubMed 26535150Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015 Sep 14;1(1):e000146. doi: 10.1136/rmdopen-2015-000146. eCollection 2015.
- Background: PubMed 11858978Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33. doi: 10.1016/s0959-8049(01)00448-8.
- Background: PubMed 8433390Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
- Background: PubMed 10782451Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597.
- Individual participant dataSharing planned: No
Related trials for Pelvic Floor Disorder
Enrolling by invitationObservational study
Long-term Pelvic Floor and Sexual Health After Obstetric Anal Sphincter Injury in Finland
Obstetric Anal Sphincter Injury, Sexual Dysfunction and the Mode of Deliveries
Recruiting
Pelvic Floor Muscle Training During Pregnancy
Urinary Incontinence, Anal Incontinence
Recruiting
Therapeutic Exercise for Postpartum Recovery
Postpartum Period, Pelvic Floor Disorders
Not yet recruitingObservational study
Pelvic Floor Ultrasound Before Induction of Labour and Labour Outcome
Labor, Pelvic Floor Disorder
RecruitingObservational study
Pelvic Floor Rehabilitation of Female Pelvic Floor Dysfunction
Pelvic Floor Disorders, Pelvic Organ Prolapse
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Signe Nilssen Stafne study chair
St. Olavs Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pelvic floor muscle training rehabilitation in people with Pelvic Floor Disorder and Female Pelvic Floor Dysfunction, run by St. Olavs Hospital at 2 sites in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility - participants willingness to be included (time frame: The time frame is pre-defined as one year recruitment period). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06786091, which also lists 58 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026; AzTrials last refreshed its copy on 26 Oct 2026.